Prognostic value of the immune target CEACAM6 in cancer : a meta-analysis
© The Author(s), 2022..
BACKGROUND: Identification of membrane proteins differentially expressed on tumor cells is a key step in drug development. The carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a cell adhesion protein belonging to the immunoglobulin superfamily. Here, we explore the prognostic role CEACAM6 expression on patient outcome in cancer.
METHODS: A systematic search for studies evaluating the association between tumor expression of CEACAM6 and overall survival (OS) and disease-free survival (DFS) was performed. Hazard ratios (HR) were pooled in a meta-analysis using generic inverse variance and random effect modeling. Subgroup analyses were conducted based on tumor type and method of HR extraction.
RESULTS: Sixteen studies met the inclusion criteria. CEACAM6 expression was associated with worse OS [HR = 1.96, 95% confidence interval (CI) = 1.51-2.53], and DFS (HR = 2.49, 95% CI = 2.01-3.07) with subgroup analysis showing no significant differences between disease site subgroups.
CONCLUSIONS: High expression of CEACAM6 is associated with worse OS and DFS in different malignancies. CEACAM6 is a target for the future development of novel therapeutics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Therapeutic advances in medical oncology - 14(2022) vom: 11., Seite 17588359211072621 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Burgos, Miguel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CEACAM6 |
|---|
| Anmerkungen: |
Date Revised 30.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/17588359211072621 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336173202 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336173202 | ||
| 003 | DE-627 | ||
| 005 | 20231225231533.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/17588359211072621 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1120.xml |
| 035 | |a (DE-627)NLM336173202 | ||
| 035 | |a (NLM)35082925 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Burgos, Miguel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic value of the immune target CEACAM6 in cancer |b a meta-analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), 2022. | ||
| 520 | |a BACKGROUND: Identification of membrane proteins differentially expressed on tumor cells is a key step in drug development. The carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a cell adhesion protein belonging to the immunoglobulin superfamily. Here, we explore the prognostic role CEACAM6 expression on patient outcome in cancer | ||
| 520 | |a METHODS: A systematic search for studies evaluating the association between tumor expression of CEACAM6 and overall survival (OS) and disease-free survival (DFS) was performed. Hazard ratios (HR) were pooled in a meta-analysis using generic inverse variance and random effect modeling. Subgroup analyses were conducted based on tumor type and method of HR extraction | ||
| 520 | |a RESULTS: Sixteen studies met the inclusion criteria. CEACAM6 expression was associated with worse OS [HR = 1.96, 95% confidence interval (CI) = 1.51-2.53], and DFS (HR = 2.49, 95% CI = 2.01-3.07) with subgroup analysis showing no significant differences between disease site subgroups | ||
| 520 | |a CONCLUSIONS: High expression of CEACAM6 is associated with worse OS and DFS in different malignancies. CEACAM6 is a target for the future development of novel therapeutics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CEACAM6 | |
| 650 | 4 | |a disease outcome | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a meta-analysis | |
| 700 | 1 | |a Cavero-Redondo, Iván |e verfasserin |4 aut | |
| 700 | 1 | |a Álvarez-Bueno, Celia |e verfasserin |4 aut | |
| 700 | 1 | |a Galán-Moya, Eva María |e verfasserin |4 aut | |
| 700 | 1 | |a Pandiella, Atanasio |e verfasserin |4 aut | |
| 700 | 1 | |a Amir, Eitan |e verfasserin |4 aut | |
| 700 | 1 | |a Ocaña, Alberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic advances in medical oncology |d 2009 |g 14(2022) vom: 11., Seite 17588359211072621 |w (DE-627)NLM19877978X |x 1758-8340 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g day:11 |g pages:17588359211072621 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/17588359211072621 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |b 11 |h 17588359211072621 | ||